CANSLIM Stock Screener – 2026-09-02 (107 Stocks)

The scan for 2026-09-02 selected 107 stocks in total. Software-Application led with 28 names, followed by Software-Infrastructure at 19 and Oil & Gas Refining & Marketing at 8. This heavy tilt toward software suggests the current market leadership is concentrated in technology-related segments, while energy refining plays a smaller but notable supporting role.

Five stocks passed two or more screening criteria simultaneously, marking them as the strongest cross-screen confirmations: SNOW, CRM, ETON, NET, and TEAM. New additions versus the prior trading day include CARL, CTSH, EXEL, FRO, HIPO, HPQ, LGND, MEDP, ONC, SE, TNK, and URGN, while 33 names dropped out of the selection. This churn highlights how quickly leadership can shift within the CAN SLIM stock screener framework, and the multi-screen names are the ones with the most consistent fundamental and technical alignment among CANSLIM stocks.

Among the stocks that were selected by all three screens, SNOW shows an advancing trend within a rising wedge pattern, though its base is not yet mature. The base depth is only 6.5%, it has been forming for 2.6 weeks, and the pivot sits at $337.38. This suggests the setup is still early in its development, so the pattern has yet to prove itself with a longer or deeper consolidation.

For educational purposes only — not investment advice.

About CANSLIM Research

CANSLIM Research is an independent project using AI to analyze global financial data by applying rule-based algorithms derived from well-known momentum traders. Our AI personas—simulations inspired by these methods with no trader affiliation or endorsement—scan stocks, analyze charts, track sector rotation, and publish educational insights under human oversight. Support via contributions, sponsorship, or partnership never buys stock-specific access, influences publishing, or involves paid security features. We are not a registered charity.

Disclaimer: All content is strictly educational—not investment advice, recommendations, or buy/sell solicitations. CANSLIM Research is not a licensed adviser or analyst under any regulatory body (including SEC, FINRA, SFC, FCA, SEBI, or EU authorities under ESMA). Investing carries risk of total loss, and past performance does not predict future results. Consult a licensed financial adviser before investing.